Effects of levothyroxine treatment on biochemical and hemostasis parameters in patients with hypothyroidism

European Journal of Endocrinology

Volumn 152, Issue 3, 2005, Pages 355-361

  Gullu, Sevim ^a   Sav, Hasan ^a   Kamel, Nuri ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; BIOCHEMICAL MARKER; BLOOD CLOTTING FACTOR 8; CHOLESTEROL; CREATINE KINASE; CREATININE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LACTATE DEHYDROGENASE; LEVOTHYROXINE; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITROGEN; PROTHROMBIN; THROMBOPLASTIN; THYROTROPIN; TRIACYLGLYCEROL; UREA; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BIOCHEMISTRY; BLEEDING TIME; BLOOD CLOTTING DISORDER; BLOOD CLOTTING TIME; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DATA ANALYSIS; DRUG MECHANISM; EUTHYROIDISM; FEMALE; HEMATOLOGICAL PARAMETERS; HEMOSTASIS; HORMONE SUBSTITUTION; HUMAN; HUMAN CELL; HYPOTHYROIDISM; LACTATE DEHYDROGENASE BLOOD LEVEL; LIPID BLOOD LEVEL; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; STATISTICAL SIGNIFICANCE; THROMBOCYTE COUNT; THYROTROPIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL;

ADULT; AGED; FACTOR VIII; FEMALE; HEMOSTASIS; HUMANS; HYPOTHYROIDISM; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; THYROID FUNCTION TESTS; THYROID GLAND; THYROXINE; VON WILLEBRAND FACTOR;

EID: 15944378163     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.1.01857     Document Type: Article

References (37)

1. Ford HC & Carter JM. Haemostasis in hypothyroidism. Postgraduate Medical Journal 1990 66 280-284.
2. Myrub B, Bregengard C & Faber J. Primary haemostasis in thyroid disease. Journal of Internal Medicine 1995 238 59-63.
3. Hofbauer LC & Heufelder AE. Coagulation disorders in thyroid diseases. European Journal of Endocrinology 1997 136 1-7.
4. Jakway JL. Acquired von Willebrand's disease. Hematology/Oncology Clinics of North America 1992 6 1409-1419.
5. Palareti G, Biagi G, Legnani C, Bianchi D, Serra D, Savini R & Coccheri S. Association of reduced factor VIII with impaired platelet reactivity to adrenalin and collagen after total thyroidectomy. Thrombosis and Haemostasis 1989 62 1053-1056.
6. Attivissimo LA, Lichtman SM & Klein I. Acquired von Willebrand's syndrome causing a hemorrhagic diathesis in a patient with hypothyroidism. Thyroid 1995 5 399-401.
7. Michiels JJ, Schroyens W, Berneman Z & van der Planken M. Acquired von Willebrand syndrome type 1 in hypothyroidism: reversal after treatment with thyroxine. Clinical and Applied Thrombosis Hemostasis 2001 7 113-115.
8. Setian N, Tanaka CM, Damiani D, Dichtchekenian V, Carneiro JD & D'Amico EA. Hypopituitarism, deficiency of factors V and VIII and von Willebrand factor: an uncommon association. Journal of Pediatric Endocrinology and Metabolism 2002 15 331-333.
9. Masunaga R, Nagasaka A, Nakai A, Kotake M, Sawai Y, Oda N, Mokuno T, Shimazaki K, Hayakawa N, Kato R, Hirano E, Hagiwara M & Hidaka H. Alteration of platelet aggregation in patients with thyroid disorders. Metabolism 1997 46 1128-1131.
10. Chadarevian R, Bruckert E, Ankri A, Beucler I, Giral P & Turpin G. Relationship between thyroid hormones and plasma D-dimer levels. Thrombosis Haemostasis 1998 79 99-103.
11. Chadarevian R, Bruckert E, Giral P & Turpin G. Relationship between thyroid hormones and fibrinogen levels. Blood Coagulation and Fibrinolysis 1999 10 481-486.
12. Muller B, Tsakiris D, Roth C, Guglielmetti M, Staub J & Marbet M. Haemeostatic profile in hypothyroidism as potential risk factor for vascular or thrombotic disease. European Journal of Clinical Investigation 2001 31 131-137.
13. Chadarevian R, Bruckert E, Leenhardt L, Giral P, Ankri A & Turpin G. Components of fibrinolytic system are differently altered in moderate and severe hypothyroidism. Journal of Clinical Endocrinology and Metabolism 2001 86 732-737.
14. Erem C, Kavgaci H, Ersoz HO, Hacihasanoglu A, Ukinc K, Karti SS, Deger O & Telatari M. Blood coagulation and fibrinolytic activity in hypothyroidism. International Journal of Clinical Practice 2003 57 78-81.
15. Rennie JA, Bewsher PD, Murchison LE & Ogston D. Coagulation and fibrinolysis in thyroid disease. Acta Haematologia 1978 59 171-177.
16. Shih CH, Chen SL, Yen CC, Huang YH, Chen CD, Lee YS & Lin KH. Thyroid hormone receptor-dependent transcriptional regulation of fibrinogen and coagulation proteins. Journal of Clinical Endocrinology and Metabolism 2004 145 2804-2814.
17. Surks MI, Ortiz E, Daniels GH, Savin CT, Col NF, Cobin RH, Franklyn JA, Hershman JM, Burman KD, Denke MA, Gorman C, Cooper RS & Weissman NJ. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. Journal of the American Medical Association 2004 291 228-238.
18. Woeber KA. Subclinical thyroid dysfunction. Archives of Internal Medicine 1997 157 1065-1068.
19. Arem R & Escalante D. Subclinical hypothyroidism: epidemiology, diagnosis, and significance. Advances in Internal Medicine 1996 41 213-250.
20. Althaus BU, Staub JJ, Ryff-de Leche A, Oberhansli A & Stahelin HB. LDL/HDL changes in subclinical hypothyroidism: possible risk factor for coronary heart disease. Clinical Endocrinology 1988 28 157-163.
21. Hak AE, Pols HA, Visser TJ, Drexhage HA, Holman A & Wittem A. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam study. Annals of Internal Medicine 2000 132 270-278.
22. Vanderpump MPJ, Tunbridge WMG, French JM, Appleton D, Bates D, Clark F, Grimley Evans J, Rodgers H, Tunbridge F & Young ET. The development of ischemic heart disease in relation to autoimmume thyroid disease in a 20-year follow-up study of an English community. Thyroid 1996 6 155-160.
23. Verhelst J, Berwaerts J, Marescau B, Abs R, Neels H, Mahler C & De Deyn PP. Serum creatine, creatinine and other guanidino compounds in patients with thyroid dysfunction. Metabolism 1997 46 1063-1067.
24. Beyer IW, Karmali R, Demeester-Mirkine N, Cogan E & Fuss MJ. Serum creatine kinase levels in overt and subclinical hypothyroidism. Thyroid 1998 8 1029-1031.
25. Monzani F, Caraccio N, Siciliano G, Manca L, Murri L & Ferrannini E. Clinical and biochemical features of muscle dysfunction in subclinical hypothyroidism. Journal of Clinical Endocrinology and Metabolism 1997 82 3315-3318.
26. Villabona C, Sahun M, Roca M, Mora J, Gomez N, Gomez JM & Soler J. Blood volumes and renal function in overt and subclinical primary hypothyroidism. American Journal of Medical Sciences 1999 318 277-280.
27. Canturk Z, Cetinarslan B, Tarkun I, Canturk NZ, Ozden M & Duman C. Hemostatic system as a risk factor for cardiovascular disease in women with subclinical hypothyroidism. Thyroid 2003 13 971-977.
28. Chu JW & Crapo LM. The treatment of subclinical hypothyroidism is seldom necessary. Journal of Clinical Endocrinology and Metabolism 2001 86 4591-4599.
29. Meier C, Staub JJ, Roth CB, Guglielmetti M, Kunz M, Miserez AR, Drewe J, Huber P, Herzog R & Muller B. TSH-controlled L-thyroxine therapy reduces cholesterol levels and clinical symptoms in subclinical hypothyroidism: a double-blind, placebo-controlled trial (Basel Thyroid Study). Journal of Clinical Endocrinology and Metabolism 2001 86 4860-4866.
30. McDermott MT & Ridgway EC. Subclinical hypothyroidism is mild thyroid failure and should be treated. Journal of Clinical Endocrinology and Metabolism 2001 86 4585-4590.
31. Danese MD, Ladenson PW, Meinert CL & Powe NR. Clinical Review 115: Effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure: a quantitative review of the literature. Journal of Clinical Endocrinology and Metabolism 2000 85 2993-3001.
32. Bell GM, Todd WTA, Forfar JC, Martyn C, Wathen CG, Gow S, Riemersma R & Toft AD. End-organ responses to thyroxine therapy in subclinical hypothyroidism. Clinical Endocrinology 1985 22 83-89.
33. Cooper DS, Halpern R, Wood LC, Levin AA & Ridgway EC. L-Thyroxine therapy in subclinical hypothyroidism. A double-blind, placebo-controlled trial. Annals of Internal Medicine 1984 101 18-24.
34. Franklyn JA, Daykin J, Betteridge J, Hughes EA, Holder R, Jones SR & Sheppard MC. Thyroxine replacement therapy and circulating lipid concentrations. Clinical Endocrinology 1993 38 453-459.
35. Nystrom E, Caidahl K, Fager G, Wikkelso C, Lundberg PA & Lindstedt G. A double-blind cross-over 12-month study Of L-thyroxine treatment of women with 'subclinical' hypothyroidism. Clinical Endocrinology 1988 29 63-75.
36. Kong WM, Sheikh MH, Lumb PJ, Freedman DB, Danielle B, Crook M, Dore CJ & Finer N. A 6-month randomized trial of thyroxine treatment in women with mild subclinical hypothyroidism. American Journal of Medicine 2002 112 348-354.
37. Caraccio N, Ferrannini E & Monzani F. Lipoprotein profile in subclinical hypothyroidism: response to levothyroxine replacement, a randomized placebo-controlled study. Journal of Clinical Endocrinology and Metabolism 2002 87 1533-1538.